To read the full story, subscribe or sign in.

Iksuda advancing lead ADC to the clinic with $47M series A financing

June 8, 2021

LONDON – Iksuda Therapeutics Ltd. sealed its transition from technology licensing company to antibody-drug conjugate (ADC) development specialist, closing a $47 million series A financing to move the lead program, IKS-03, into the clinic.

BioWorld Asia Financings Cancer Antibody-drug conjugate Series A

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

Businesspeople shaking hands, meeting with cityscape, charts

Deals and an M&A strengthen end-of-year numbers

BioWorld

Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...

Neutrophils put the brakes on fat loss

BioWorld Science

Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...